clarithromycin has been researched along with ketoconazole in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 10 (31.25) | 29.6817 |
| 2010's | 20 (62.50) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Jia, L; Sun, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Oster, G; Thompson, D | 1 |
| Douya, R; Mushiroda, T; Nagata, O; Takahara, E | 1 |
| Barrett, JS; Bhargava, VO; Chapel, S; Hardy, P; Leroy, B; Montay, G; Noveck, R; Shi, J; Sica, D; Swan, SK | 1 |
| Bodmer, M; Brecht, K; Bur, D; Krähenbühl, S; Tsakiris, DA; Zahno, A | 1 |
| Becka, M; Kubitza, D; Mueck, W | 1 |
| Hall, SD; Higgins, JW; Ke, AB; Zamek-Gliszczynski, MJ | 1 |
| Higgins, JW; Ke, AB; Zamek-Gliszczynski, MJ | 1 |
| Buckley, DB; Isringhausen, CD; Ogilvie, BW; Vermeer, LM | 1 |
| Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X | 1 |
| Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S | 1 |
| Alexeev, A; Brink, H; Campbell, B; Islam, M; Lam, W; McFarland, B; Mezencev, R; Sulchek, T; Tasadduq, B; Waller, EK | 1 |
| Ge, W; Jiang, Q; Xu, R | 1 |
| Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK | 1 |
| Cushman, M; Fan, BZ; Han, X; Kong, FS; Li, YX; Liang, JH; Lv, W; Ma, CX; Tian, JC | 1 |
| Cushman, M; Fan, BZ; Guo, SY; Kong, FS; Li, XM; Li, YX; Liang, JH; Lv, W; Zhang, J | 1 |
1 review(s) available for clarithromycin and ketoconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for clarithromycin and ketoconazole
| Article | Year |
|---|---|
Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Biological Availability; Clarithromycin; Drug Administration Schedule; Drug Interactions; Electrocardiography; Female; Humans; Ketoconazole; Ketolides; Kidney Diseases; Male; Metabolic Clearance Rate; Middle Aged | 2005 |
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Middle Aged; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Young Adult | 2013 |
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Glycine; Humans; Ketoconazole; Male; Middle Aged; Models, Biological; Neoplasms; Proteasome Inhibitors; Rifampin | 2018 |
28 other study(ies) available for clarithromycin and ketoconazole
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Use of terfenadine and contraindicated drugs.
Topics: Anti-Bacterial Agents; Antifungal Agents; Clarithromycin; Contraindications; Drug Interactions; Drug Utilization; Erythromycin; Histamine H1 Antagonists; Humans; Itraconazole; Ketoconazole; Pharmaceutical Services; Product Labeling; Retrospective Studies; Terfenadine; Troleandomycin | 1996 |
The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate.
Topics: Administration, Oral; Animals; Antiemetics; Area Under Curve; Benzamides; Benzyl Compounds; Cimetidine; Cisapride; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dealkylation; Enzyme Stability; Erythromycin; Hot Temperature; Isoenzymes; Ketoconazole; Male; Microsomes, Liver; Mixed Function Oxygenases; Morpholines; Oxygen; Oxygenases; Rats; Rats, Sprague-Dawley | 2000 |
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Clarithromycin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Models, Molecular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrroles; Recombinant Proteins; Simvastatin; Substrate Specificity; Ticlopidine | 2010 |
Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.
Topics: Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Design; Drug Interactions; Enzyme Inhibitors; Europe; Humans; Itraconazole; Ketoconazole; United States; United States Food and Drug Administration | 2014 |
Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
Topics: Animals; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Itraconazole; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Organic Anion Transporters; Organic Cation Transporter 1 | 2014 |
Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Topics: Biological Transport; Cell Line; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HEK293 Cells; Humans; Itraconazole; Ketoconazole; Membrane Transport Proteins; Ritonavir | 2016 |
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software | 2018 |
Microfluidic cell sorting by stiffness to examine heterogenic responses of cancer cells to chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Biomechanical Phenomena; Caffeic Acids; Cell Separation; Cell Survival; Clarithromycin; Daunorubicin; Drug Combinations; Drug Resistance, Neoplasm; Elastic Modulus; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Jurkat Cells; K562 Cells; Ketoconazole; Lab-On-A-Chip Devices; Neoplasm Proteins | 2018 |
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Computer Simulation; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Factor Xa Inhibitors; Humans; Ketoconazole; Liver Diseases; Male; Models, Biological; Renal Insufficiency; Ritonavir; Rivaroxaban | 2018 |
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Topics: Administration, Oral; Adult; Aged; Alkynes; Aminopyridines; Area Under Curve; Benzimidazoles; Benzoxazines; Bosentan; Clarithromycin; Computer Simulation; Cyclin-Dependent Kinases; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Modafinil; Models, Biological; Rifampin; Verapamil | 2020 |
Design, synthesis and structure-activity relationships of novel macrolones: Hybrids of 2-fluoro 9-oxime ketolides and carbamoyl quinolones with highly improved activity against resistant pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Bacterial; Ketolides; Microbial Sensitivity Tests; Molecular Structure; Oximes; Quinolones; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2019 |
Synthesis and structure-bactericidal activity relationships of non-ketolides: 9-Oxime clarithromycin 11,12-cyclic carbonate featured with three-to eight-atom-length spacers at 3-OH.
Topics: Anti-Bacterial Agents; Bacteria; Clarithromycin; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2019 |